Episodes

  • The Switch Pitch: Biosimilars In Real World HS Care PART 3

    The Switch Pitch: Biosimilars In Real World HS Care PART 3
    Jul 7 2026

    🎙️ HS & Biosimilars: The Switch Pitch — Part 3

    Final drop, biggest pearls. 💎

    Is HS is the new acne? How can we treat early, treat seriously, and help prevent long-term scarring—physical and emotional?

    In Part 3 of our real-world HS conversation, Skin and Joints Podcast F aculty Dr. Lauren Lam and Dr. Marni Wiseman bring the discussion home with practical, clinic-ready insights for dermatologists navigating biosimilars, biologics, comorbidities, obesity, smoking, PSP realities, and the art of building trust over time.

    From why GLP-1s are not a substitute for HS-directed biologic therapy, to how to incorporate non-stigmatizing conversations around obesity and smoking cessation in the clinic, this episode gets into the real-world nuance that does not always fit neatly into an algorithm.

    And when it comes to choosing between a TNF biosimilar and IL-17 options? How dos comorbidities, contraindications, access, PSP fit, disease severity, and the patient sitting in front of you all factor in for each? Find out here. 👩‍⚕️🧠

    Learning Objectives
    By the end of this episode, listeners will be able to:

    1. Describe practical considerations for managing HS beyond acute flares, including longitudinal disease control and early biologic initiation in appropriate patients.
    2. Discuss how GLP-1 therapies may fit as adjunctive care in select HS patients, while recognizing that they do not replace targeted HS biologic or biosimilar therapy.
    3. Apply non-stigmatizing, patient-centred approaches when discussing obesity and smoking cessation in HS care.
    4. Identify key factors that influence selection between TNF biosimilars and IL-17 therapies, including comorbid IBD, rheumatoid arthritis, contraindications, candidiasis risk, disease severity, and access.
    5. Recognize the role of PSPs, samples, dose optimization, and follow-up planning in improving real-world HS treatment continuity.

    #SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #Biosimilars #Biologics #InflammatorySkinDisease #MedicalEducation #DermTwitter #DermatologyEducation #PatientCentredCare #RealWorldDermatology #PSP #IL17 #TNF #ClinicalPearls 💉🧬🎙️

    ABOUT Dr. Lauren Lam BScH, MD, FRCPC

    ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB

    Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.

    Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.

    ABOUT Dr. Marni C. Wiseman MD FRCPC DABD

    Associate Professor, Section Head Dermatology University of Manitoba

    Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research

    Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.

    Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris.

    Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.

    EPISODE SUPPORTED BY CELLTRION CANADA

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca
    Show More Show Less
    17 mins
  • The Switch Pitch: Biosimilars In Real World HS Care PART 2

    The Switch Pitch: Biosimilars In Real World HS Care PART 2
    Jun 30 2026
    🎙️ PART 2: HS & Biosimilars: The Switch Pitch — Real-World Pearls from the Clinic 💉🔥🧴 In Part 2 of our HS and biosimilars conversation, we’re getting practical — very practical. 🎧🩺 Faculty Dr. Lauren Lam and Dr. Marni Wiseman join the Skin and Joints Podcast to unpack what really matters when biosimilars move from policy, paperwork, and prescribing forms… into the real lives of patients with hidradenitis suppurativa. 📋➡️💪 From the science of biosimilarity and extrapolating evidence across inflammatory diseases, to the clinic-level details dermatologists cannot afford to overlook — injection pain, citrate-free formulations, device ergonomics, dosing convenience, patient support programs, rural drug delivery, reload strategies, and yes… whether the PSP actually calls the patient back. ☎️🚚💉 Because in HS, the best biologic or biosimilar is not just about the molecule. It is about momentum, access, trust, support, and getting treatment into the patient’s hands before they disappear from the care journey. 🧭🤝 The conversation also takes a timely turn into obesity, systemic inflammation, GLP-1/GIP therapies, and whether metabolic care may become part of the next frontier in HS management. ⚖️🔥🔬 Consider this your field guide to biosimilar switching in HS — with clinic hot tips, PSP reality checks, and a reminder that sometimes the smallest formulation detail can make the biggest difference to the person injecting every week. 💡💉🙌 Learning Objectives: By the end of this episode, listeners will be able to: Explain how biosimilar evidence may be extrapolated across inflammatory diseases and how this applies to real-world HS care. 🔬Identify key formulation and device factors that may influence patient comfort, adherence, and treatment experience with adalimumab biosimilars. 💉Describe the role of patient support programs (PSPs) in treatment initiation, onboarding, access, monitoring, and long-term engagement for patients with HS. 🤝Recognize practical barriers to biosimilar use in HS, including injection training, treatment delays, rural/remote medication delivery, and patient disillusionment. 🚚Discuss emerging considerations around obesity, systemic inflammation, and GLP-1/GIP therapies as part of the evolving HS care conversation. ⚖️🔥= #SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #MedicalDermatology #Biosimilars #Adalimumab #InflammatorySkinDisease #DermatologistEducation #RealWorldDermatology #PatientSupportPrograms #Biologics #ClinicalPearls #DermatologyPodcast #HSManagement 🧴💉🔥🎧🩺 ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date. Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs. ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice. Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery. EPISODE SUPPORTED BY CELLTRION CANADA 📻www.skinandjoints.ca ✉️info@skinandjoints.ca 📻www.skinandjoints.ca✉️info@skinandjoints.ca
    Show More Show Less
    19 mins
  • Cross Border Talk with Raj Chovatiya and Melinda Gooderham: Hands On, Gloves Off

    Cross Border Talk with Raj Chovatiya and Melinda Gooderham: Hands On, Gloves Off
    Jun 22 2026
    🎙️🇨🇦🇺🇸. Hands On, Gloves Off: Cross-Border Talk on Atopic Hand Eczema We’re coming to you from the heart of Music City, Nashville 🎸 — but don’t worry, this Cross-Border Talk is not about trade, tariffs, or hockey rivalries. This time, it’s all hands on deck. ✋🇨🇦🇺🇸 In this episode of the Skin and Joints Podcast from RAD 2026, our Cross-Border Dermatologist Faculty Dr. Raj Chovatiya from the U.S. joins Canadian favourite Dr. Melinda Gooderham for a lively, practical, and focused conversation on atopic hand eczema, chronic hand eczema, and fresh week 32 data exploring tralokinumab in this challenging and high-burden body site. Hands may represent a small body surface area, but they carry an outsized burden. They are exposed, functional, visible, constantly irritated, and central to work, hobbies, caregiving, gardening, handshakes, procedures, and everyday life. In other words: when the hands are flaring, patients are not just uncomfortable — they are often functionally sidelined. 🧤🌱 This episode goes beyond the usual did the trial hit the endpoint discussion and digs into the real-world so what? You’ll hear how the week 32 data may help frame expectations, why some patients may need more time before being labelled non-responders, how itch and pain improvements matter alongside clearance, and how shared decision-making can turn clinical trial endpoints into conversations patients actually understand. 📊🩺 The discussion also gets practical on where tralokinumab may fit alongside emerging topical options like delgocitinib, how to think about atopic hand eczema versus broader chronic hand eczema phenotypes, and why a back to basics approach remains timeless advice when patients are not responding as expected. 🔍 From Nashville notes to Monday morning clinic, this Cross-Border Talk offers a hands-on look at atopic hand eczema — with just enough clinical soil turned over to leave you wanting the full episode. 🎙️✋ Learning Objectives 🎯 After listening to this episode, listeners will be able to: Describe the clinical and functional burden of atopic hand eczema✋, including why hands represent a uniquely challenging and high-impact treatment site despite limited body surface area involvement.Summarize key elements of the week 32 tralokinumab data in atopic hand eczema📊, including trial design, patient population, efficacy signals, symptom outcomes, and tolerability considerations.Interpret week 16 versus week 32 response data through a real-world clinical lens🕒, including how to counsel partial responders and avoid prematurely labelling treatment as failure.Integrate patient-reported outcomes into treatment decision-making🗣️, particularly itch, pain, function, visibility, and the patient’s ability to return to meaningful daily activities.Differentiate treatment considerations for atopic hand eczema versus broader chronic hand eczema🧩, including when topical, systemic, or combination strategies may be appropriate.Apply practical clinic-based reassessment strategies for patients with persistent hand eczema🔍, including evaluation for irritant contact dermatitis, allergic contact dermatitis, occupational exposures, and ongoing trigger management. ABOUT Dr. Raj Chovatiya, MD, PhD, MSCI Associate Professor | Rosalind Franklin University of Medicine and Science Chicago Medical School Founder and Director | Center for Medical Dermatology + Immunology Research Chicago, USA Raj Chovatiya, MD, PhD, MSCI is Associate Professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois. His clinical and research focus includes the intersection of cutaneous immunology and inflammatory disease. He received his MD and PhD in immunology from Yale and completed his residency, postdoctoral research fellowship, and MS in Clinical Investigation at Northwestern University where he also served as Chief Resident. Dr. Chovatiya has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, exploring health and social disparities, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been nationally and internationally recognized for his contributions as a clinician, educator, researcher, and leader. ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal ...
    Show More Show Less
    28 mins
  • The Switch Pitch: Biosimilars In Real World HS Care PART 1

    The Switch Pitch: Biosimilars In Real World HS Care PART 1
    Jun 18 2026
    🎙️ PART 1: Real-World Biosimilar Care in HS with Dr. Lauren Lam and Dr. Marni Wiseman HS has officially entered the Skin and Joints chat — and it did not come quietly. In this special Part 1 episode, we welcome back two Skin and Joints Podcast Faculty favourites, dermatologists Dr. Lauren Lam and Dr. Marni Wiseman, for a practical, candid, and refreshingly real-world conversation on hidradenitis suppurativa, biologics, and the evolving role of biosimilars in Canadian care. From delayed diagnosis and cumulative life-course impact to biologic timing, patient expectations, injection burden, access barriers, and the art of asking, “How sick of this are you?” — this episode digs into the clinical realities that do not always fit neatly into trial endpoints. Dr. Lam and Dr. Wiseman share frontline insights on why HS is uniquely challenging, why earlier intervention may change the patient journey, and how biosimilars are reshaping access, dosing conversations, and practical treatment decisions. Expect clinical pearls, a few myth-busting moments, and clinic hot tips you can actually use — from identifying the right referral pathway, to setting realistic goals, minimizing injection burden, considering dose optimization, and translating trial endpoints into real-life wins for patients. Also discussed: tennis dreams, cottage shade, citrate-free formulations, the joy of one injection instead of two, and why HS care is rarely a solo sport. 🎾🌿💉 Learning Objectives After listening to this episode, learners should be able to: Describe why hidradenitis suppurativa is uniquely challenging to manage compared with other chronic inflammatory skin diseases, including the role of delayed diagnosis, comorbidities, surgery, pain, drainage, scarring, and quality-of-life burden.Identify real-world factors that influence biologic initiation in HS, particularly in moderate disease, including patient-reported impact, flare burden, treatment goals, and the importance of earlier intervention when clinically appropriate.Explain the current relevance of adalimumab biosimilars in Canadian HS care, including access, reimbursement, compassionate support, patient counselling, and confidence in biosimilar efficacy and safety.Apply practical counselling strategies for patients starting or switching to biosimilar therapy, including how to discuss expectations, injection burden, pain, formulation differences, and meaningful patient-centred outcomes.Recognize clinic-ready strategies to optimize HS care, including referral tips, patient-centred goal setting, realistic timelines for improvement, combination therapy considerations, and individualized dose optimization in patients with persistent disease activity. #SkinAndJointsPodcast #HidradenitisSuppurativa #HSAwareness #Biosimilars #Adalimumab #Dermatology #RheumDerm #InflammatoryDisease #RealWorldEvidence #PatientCenteredCare #BiologicTherapy #CanadianDermatology #MedicalPodcast #ClinicianEducation #ClinicHotTips #AccessToCare Episode supported by Celltrion Canada. ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date. Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs. ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice. Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery. EPISODE SUPPORTED BY ...
    Show More Show Less
    24 mins
  • The Great Atopic Dermatitis Dose Debate: Escalate, De-escalate, or Hold Steady?

    The Great Atopic Dermatitis Dose Debate: Escalate, De-escalate, or Hold Steady?
    Jun 3 2026
    🎙️The Great Dose Debate: Escalate, De-escalate, or Hold Steady?

    In this final episode of our AAD 2026 atopic dermatitis post-game poster series, we’re joined by dermatologist Dr. Julien Ringuet from Quebec City for a practical, no-fluff breakdown of the JADE REAL analysis — and what flexible abrocitinib dosing may actually mean when Monday morning clinic rolls around.

    Because in real life, patients do not always follow a tidy trial algorithm. Symptoms flare, itch keeps people up, adherence shifts, priorities change, and sometimes the “right” dose is less of a fixed destination and more of a GPS recalculating in real time. 🧭

    Dr. Ringuet walks us through the clinical “so what” behind dose escalation and de-escalation, explaining why moving from 100 mg to 200 mg — or stepping down from 200 mg to 100 mg — should not automatically be seen as failure, overtreatment, or backpedalling.

    Instead, flexible dosing may be part of a thoughtful, shared decision-making strategy that better reflects the messy, dynamic reality of moderate-to-severe atopic dermatitis care.

    We cover how early reassessment, patient-reported outcomes, itch, sleep, EASI trends, payer flexibility, and treat-to-target thinking all fit into the bigger picture. And yes, we also discuss the real-world art of knowing when to push, when to pause, and when to test the waters with a lower dose. 🌊

    ✨ Learning Objectives

    By the end of this episode, listeners should be able to:

    1. Describe how the JADE REAL study design reflects real-world clinical decision-making in moderate-to-severe atopic dermatitis.
    2. Explain why dose escalation and de-escalation with abrocitinib may represent intentional treatment optimization rather than treatment failure.
    3. Identify practical clinical scenarios where starting at 100 mg versus 200 mg may be appropriate.
    4. Discuss how early follow-up, patient-reported outcomes, itch, sleep, and quality-of-life measures can help guide dose adjustment decisions.
    5. Recognize key limitations of open-label, real-world evidence when translating study findings into clinical practice.
    6. Apply a treat-and-adjust approach to atopic dermatitis management using shared decision-making and individualized treatment goals.

    💡 Key Takeaway

    Flexible dosing is not a loophole — it is real-world dermatology. The win is not finding one perfect pathway for every patient; it is learning how to reassess early, individualize thoughtfully, and adjust with purpose. 🩺

    🎧 Tune in for practical pearls, real-world nuance, and Dr. Ringuet’s post-game analysis on what these data may mean for dermatologists managing AD in everyday practice.

    #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

    ABOUT Dr. Julien Ringuet

    Dermatologist, Quebec City, QC

    Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).


    He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).


    Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

    Supported by an IME Grant from PFIZER.



    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca
    Show More Show Less
    20 mins
  • From Clearer Skin to Better Sleep: MDA and Redefining Success in Atopic Dermatitis

    From Clearer Skin to Better Sleep: MDA and Redefining Success in Atopic Dermatitis
    Jun 1 2026
    From Clearer Skin to Better Sleep: MDA and Redefining Success in Atopic Dermatitis 🎙️

    Are We Treating Eczema… or Just Admiring Better Scores? Minimal Disease Activity in Atopic Dermatitis

    In this rapid-fire AAD poster recap, dermatologist Dr. Julien Ringuet joins the Skin and Joints podcast to unpack a big idea with a small acronym: MDA — Minimal Disease Activity.

    Borrowed from the rheumatology playbook and now making its way into dermatology, MDA asks a deceptively simple question in atopic dermatitis care: Is the patient actually doing well, or do they just look better on paper?

    Together, we dive into new treat-to-target data from the AHEAD analysis, comparing abrocitinib and dupilumab through a more holistic lens — one that includes not only skin clearance, but also itch, sleep, quality of life, and the patient’s lived experience. Spoiler: an EASI score may be impressive, but it does not tuck your patient into bed at night.

    Dr. Ringuet breaks down how MDA could help clinicians raise the bar in atopic dermatitis management, why early symptom relief matters, where oral JAK inhibitors may fit for selected patients, and why safety, comorbidities, route of administration, patient preference, and long-term strategy still deserve front-row seats in every treatment decision.

    This episode is not just about picking a winner between therapies. It is about redefining what “success” should mean in chronic inflammatory skin disease — and avoiding the trap of accepting “better” when patients are still itchy, sleepless, and sidelined from daily life.

    🎯 Learning Objectives

    By the end of this episode, listeners will be able to:

    1. Define Minimal Disease Activity in atopic dermatitis using the AHEAD treat-to-target framework, including both clinician-reported and patient-reported outcomes.
    2. Explain why MDA may offer a more patient-centred endpoint than traditional skin-only measures such as EASI 75 or EASI 90.
    3. Interpret key findings from the abrocitinib versus dupilumab analysis, including the relevance of early response, week-two separation, and multidimensional disease control.
    4. Identify patient profiles where rapid and comprehensive symptom control may influence treatment selection, while balancing safety, comorbidities, monitoring needs, access, and patient preferences.
    5. Describe practical ways to integrate a treat-to-target MDA approach into dermatology clinics, using manageable tools such as IGA/BSA or EASI, itch NRS, sleep NRS, and DLQI.
    6. Recognize the importance of avoiding therapeutic inertia when patients remain itchy, sleep-deprived, or functionally impaired despite partial improvement.
    🧠 Key Takeaway

    Minimal Disease Activity may be the dermatology upgrade we did not know we needed: less “your skin looks better” and more “are you sleeping, functioning, and living better?”

    #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

    ABOUT Dr. Julien Ringuet

    Dermatologist, Quebec City, QC

    Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).
    He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).
    Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

    Supported by an IME Grant from PFIZER.



    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca
    Show More Show Less
    22 mins
  • JAKs, Flares & Rescue Plans: The Art of the Atopic Dermatitis Dose-Down

    JAKs, Flares & Rescue Plans: The Art of the Atopic Dermatitis Dose-Down
    May 28 2026

    JAKs, Flares & Rescue Plans: The Art of the Atopic Dermatitis Dose-Down 🎙️

    In this rapid-fire post-AAD recap, dermatologist Faculty Dr. Julien Ringuet joins the Skin and Joints Podcast to tackle a question that comes up all the time in real-world atopic dermatitis care: once a patient is doing well, can we safely step down therapy without sending their skin into rebellion?

    Using newly presented data on abrocitinib dose down-titration from the JADE program, Dr. Ringuet walks through what happens when patients who respond to 200 mg transition to 100 mg for long-term maintenance—and what clinicians should do if disease control starts to slip. Spoiler: stepping down is not a cliff dive.

    Along the way, we cover the “so what?” behind the numbers: who may be a good candidate for dose reduction, how to define loss of control beyond just visible skin lesions, why itch and sleep still deserve centre stage, and how shared decision-making can turn a dosing conversation into a true treatment partnership.

    This episode is for clinicians who want to move beyond poster reading and into practical, exam-room-ready conversations about JAK inhibitors, maintenance dosing, treat-to-target thinking, flare management, and individualized care in atopic dermatitis.

    Learning Objectives 📚

    After listening to this episode, listeners should be able to:

    1. Describe the clinical rationale for considering abrocitinib dose down-titration in selected patients with atopic dermatitis.
    2. Interpret key long-term efficacy and flare data from the JADE Regimen/JADE Extend analyses in the context of real-world maintenance therapy.
    3. Identify patient factors that may support or discourage dose reduction, including depth of response, flare history, adherence, follow-up reliability, quality-of-life burden, and patient preferences.
    4. Explain how to counsel patients that step-down therapy is an option—not a guarantee—and that itch, sleep disruption, visible flare, and increased topical use can all signal loss of control.
    5. Apply a treat-to-target mindset using both clinician-reported outcomes, such as EASI, IGA, and BSA, and patient-reported outcomes, including itch, sleep, satisfaction, and quality of life.
    6. Recognize key caveats when applying clinical trial data to real-world practice, including responder-enriched populations, rescue therapy design, and as-observed analyses.

    #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

    ABOUT Dr. Julien Ringuet

    Dermatologist, Quebec City, QC

    Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).
    He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).
    Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

    Supported by an IME Grant from PFIZER.



    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca
    Show More Show Less
    26 mins
  • Quick Win, Durable Victory or Both? Rethinking Psoriasis Biologics After PSoHO

    Quick Win, Durable Victory or Both? Rethinking Psoriasis Biologics After PSoHO
    May 21 2026
    Skin, joints, and staying power—because in psoriasis, “getting clear” is only half the story. In this episode of the Skin and Joints Podcast 🎧, dermatologist Dr. Chih-ho Hong and rheumatologist Dr. May Kazem team up again for a lively, multidisciplinary deep dive into new 24-month real-world data from PSoHO 📊, an international prospective observational study of biologic-treated patients with moderate-to-severe psoriasis. The big question? Not just who gets patients clear ✨—but what gets them clear quickly ⏱️ and keeps them there for the long haul 🏃‍♂️. This analysis looks at 24-month effectiveness and durability across biologic classes, then zooms in 🔍 on several individual biologics from IL-17 to IL-23 and TNF-I . But here’s the catch—and it’s a clinically juicy one: durability was defined very stringentIly. Patients had to achieve PASI90 or PASI100 by week 12 🎯 and then maintain that same response at months 6, 12, 18, and 24 📆. In other words, this is not a “looked good once and disappeared” kind of outcome 👻. This is the biologic equivalent of showing up early, staying consistent, and never ghosting the follow-up visit ✅. Dr. Hong and Dr. Kazem bring the classic Skin and Joints perspective: how should clinicians interpret biologic class comparisons? Within class comparisons? And why does durability sound simple until you realize it rewards treatments that are both fast starters ⚡ and long-distance runners 🏃‍♀️? Expect practical pearls 💎, careful interpretation 🧠, and a reminder that real-world evidence is incredibly useful 🔬—as long as we read the fine print before declaring a winner 🏆. Based on the attached podcast conversation emphasizing multidisciplinary care, real-world caveats, patient priorities, and the importance of viewing psoriasis as more than “just skin.” 🎯 Learning Objectives After listening to this episode, learners should be able to: Describe the PSoHO study design 📊, including its role as an international, prospective, observational study of biologic-treated patients with moderate-to-severe psoriasis. Explain 24-month effectiveness and durability ⏱️, including why maintaining PASI90 or PASI100 across multiple time points is a more demanding measure of sustained treatment success. Interpret stringent durability outcomes with caution 🧠, recognizing that this definition favors therapies that achieve early clearance and then maintain it over time. Compare biologic classes and individual agents 🔍, including how performance may be understood in the context of real-world treatment decisions. Apply a multidisciplinary skin-and-joints lens , considering skin clearance, psoriatic arthritis risk, patient-reported impact, comorbidities, and treatment persistence. Recognize the strengths and limitations of real-world observational data, including confounding by indication, patient selection, and why association does not automatically equal causation #SkinAndJoints #PsoriaticArthritis #Psoriasis #Dermatology #Rheumatology #Ixekizumab #PROSPIRIT #RealWorldEvidence #InflammatoryDisease #Biologics #bDMARDs #tsDMARDs #IL17 #MedEd #HCPeducation #DermRheum #PatientCentredCare #ClinicalPractice #Podcast #Vodcast Episode supported by an IME Grant from Eli Lilly. ABOUT Dr. Chih-ho Hong, MD, FRCPC Dermatologist, Vancouver, BC Dr. Hong is a board-certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office-based dermatology clinic with a focus on clinical research. He is a Clinical Associate Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination. He is currently the Canadian representative to SPIN (The Skin Inflammation and Psoriasis International Network) – spindermatology.org Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses. ABOUT Dr. May Kazem, MD, FRCPC Rheumatologist, Vancouver, BC Dr. Mikameh “May” Kazem is a Canadian rheumatologist based in Vancouver, BC. She holds an undergraduate degree in biotechnology and a Master’s in Health Administration. She completed her Internal Medicine residency at the University of British Columbia, followed by Rheumatology fellowship ...
    Show More Show Less
    22 mins